300 results on '"Thibodeau, S. N."'
Search Results
2. Keimbahnmutationen in den Mismatch-Repair-Genen hMSH2 und hMLH1 bei sporadischen, familiären und hereditären kolorektalen Karzinomen
3. Correction: Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database (Genetics in Medicine, (2020), 22, 1, (15-25), 10.1038/s41436-019-0596-9)
4. Microsatellite Instability in Cancer of the Proximal Colon
5. HEF1, a novel target of Wnt signaling, promotes colonic cell migration and cancer progression
6. Analysis in the Prospective Lynch Syndrome Database identifies sarcoma as part of the Lynch syndrome tumor spectrum
7. Absence of PMS2 mutations in colon-CFR participants whose colorectal cancers demonstrate unexplained loss of MLH1 expression
8. The genetic basis of colorectal cancer in a population-based incident cohort with a high rate of familial disease
9. SPTLC1 and RAB7 mutation analysis in dominantly inherited and idiopathic sensory neuropathies
10. BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing
11. No fumarate hydratase (FH) mutations in hereditary prostate cancer
12. An MLH1 haplotype is over-represented on chromosomes carrying an HNPCC predisposing mutation in MLH1
13. High-throughput screening of prostate cancer risk loci by single nucleotide polymorphisms sequencing
14. H63D is an haemochromatosis associated allele
15. Exclusion of a primary gene defect at the HLA locus in familial idiopathic dilated cardiomyopathy
16. Apolipoprotein E allele in Chamorros with amyotrophic lateral sclerosis/parkinsonism-dementia complex
17. Cross-Cancer Genome-Wide Analysis of Lung, Ovary, Breast, Prostate, and Colorectal Cancer Reveals Novel Pleiotropic Associations: Cancer Research
18. Mendelian randomization study of height and risk of colorectal cancer
19. Identification of candidate genes for prostate cancer-risk SNPs utilizing a normal prostate tissue eQTL data set
20. Linkage analysis using multiple DNA polymorphic markers in normal families and in families with fragile X syndrome
21. Aberrant MEK5/ERK5 signalling contributes to human colon cancer progression via NF-κB activation
22. HDAC8 and STAT3 repress BMF gene activity in colon cancer cells
23. Mutations in AXIN2 cause colorectal cancer with defective mismatch repair by activating beta-catenin/TCF signalling (vol 26, pg 146, 2000)
24. Fine-mapping identifies multiple prostate cancer risk loci at 5p15, one of which associates with TERT expression
25. The fragile X premutation in carriers and its effect on mutation size in offspring
26. Determining the frequency of de novo germline mutations in DNA mismatch repair genes
27. Colorectal cancer cases with de novo germ-line mutations in MLH1, MSH2, and MSH6 from the Colon Cancer Family Registry.
28. Influence of KRAS and BRAF mutational status and rash on disease-free survival (DFS) in patients with resected stage III colon cancer receiving cetuximab (Cmab): Results from NCCTG N0147.
29. DNA Mismatch Repair Status and Colon Cancer Recurrence and Survival in Clinical Trials of 5-Fluorouracil-Based Adjuvant Therapy
30. Body mass index in early adulthood and colorectal cancer risk for carriers and non-carriers of germline mutations in DNA mismatch repair genes
31. Adjuvant FOLFIRI with or without cetuximab in patients with resected stage III colon cancer: NCCTG Intergroup phase III trial N0147.
32. Family-based association analysis of 42 hereditary prostate cancer families identifies the Apolipoprotein L3 region on chromosome 22q12 as a risk locus
33. Adjuvant mFOLFOX6 with or without cetuxiumab (Cmab) in KRAS wild-type (WT) patients (pts) with resected stage III colon cancer (CC): Results from NCCTG Intergroup Phase III Trial N0147.
34. Lynch syndrome TACSTD1 family with predominant colorectal cancer.
35. A novel, noninvasive, mRNA gene expression colon cancer screening methodology.
36. Analysis of time-dependent patterns of treatment effect and failure to explain the predictive role of deficient mismatch repair (dMMR) in stage II and III colon cancer (CC).
37. Adjuvant mFOLFOX6 plus or minus cetuximab (Cmab) in patients (pts) with KRAS mutant (m) resected stage III colon cancer (CC): NCCTG Intergroup Phase III Trial N0147.
38. Model-based prediction of defective DNA mismatch repair using clinicopathological variables in stage II and III colon cancers
39. Risk of cancer in MSH6 mutation carriers: an international collaboration
40. Activated EGFR as a prognostic marker in human colon cancer
41. Confirmation of deficient mismatch repair (dMMR) as a predictive marker for lack of benefit from 5-FU based chemotherapy in stage II and III colon cancer (CC): A pooled molecular reanalysis of randomized chemotherapy trials
42. Mutations in the proapoptotic BAX gene are associated with defective DNA mismatch repair and altered tumor growth rates in human colon cancers
43. EGFR expression is associated with increased cell turnover and poor histologic grade in human colon carcinomas
44. Alterations in cell proliferation and apoptosis in human colon cancers with microsatellite instability
45. Microsatellite instability but not thymidylate synthase is a prognostic variable in primary colon cancers from patients treated in 5-FU-based adjuvant studies
46. Epidermal growth factor receptor expression correlates with histologic grade but not microsatellite instability in primary colon carcinomas
47. DNA ploidy is a stronger prognostic variable compared to microsatellite instability or 18q allelic loss in patients with stages II and III colon cancer
48. The gene for HMSN2C maps to 12q23-24: A region of neuromuscular disorders
49. Prevalence and Clinical Significance of Hfe Gene Mutations in Patients With Iron Overload
50. Differential expression and allelotyping of the p73 gene in neuroblastoma.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.